Jiangsu Hengrui Pharmaceuticals' products included in the national medical insurance directory.

Jiangsu Hengrui Pharmaceuticals (01276) announced that some products of Jiangsu Hengrui Pharmaceuticals have been included in the National Medical Insurance Catalog according to the notice issued by the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security on the issuance of the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (2025)" ("National Medical Insurance Catalog"). Through medical insurance negotiations, the injection of recombinant humanized anti-HER2 monoclonal antibody, apatinib capsules, nivolumab injection, osimertinib tablets, lorlatinib, atezolizumab injection, abiraterone acetate tablets, liposomal irinotecan injection, pioglitazone metformin tablets, perfluorohexyl hexane eye drops have been included in the National Medical Insurance Catalog for the first time; the injection of trastuzumab, afatinib capsules, teicoplanin injection for new indications have been successfully included in the National Medical Insurance Catalog; the renewal of imatinib mesylate tablets, palbociclib capsules, sitagliptin phosphate tablets, remifentanil, pabrinex injection have been successfully retained in the National Medical Insurance Catalog; the addition of apatinib mesylate tablets and liposomal bupivacaine injection for new indications have been adjusted to routine catalog management.